For the second quarter of 2026, analysts expect Johnson & Johnson to report consensus revenue of $25.18 billion and adjusted EPS of $2.85, with the stock currently trading at $263.04 against an average analyst price target of $262.27.
Investors are primarily focused on the growth trajectory of the Innovative Medicine segment, specifically the sales performance of the blockbuster oncology therapy Darzalex. This focus follows a strong first quarter where pharmaceutical share gains helped offset patent headwinds from biosimilar competition for Stelara.
Furthermore, market participants are closely monitoring the MedTech division's integration of recent acquisitions, such as Shockwave Medical, to gauge its contribution to long-term operational margin expansion.